The Price of Survival: Insulin Costs Are Crushing Middle-Class Americans

ARLINGTON, Va. – June 23, 2026 – For millions of Americans living with diabetes, the daily calculus of survival is becoming increasingly untenable. A stark new survey reveals that the cost of insulin, a century-old lifesaving drug, is pushing even middle-class families to the financial brink, forcing unthinkable choices between medicine, food, and other basic needs.

New polling released by the American Diabetes Association (ADA) paints a grim picture of a crisis that policy has only partially addressed. While a $35 monthly cap on insulin for Medicare recipients has provided relief for seniors, a vast population covered by private and employer-sponsored insurance remains exposed to crippling costs. The survey found that nearly 40 percent of insulin users polled are paying more than $150 per month, with some facing bills upwards of $400. This financial strain is not just a problem for the lowest earners; it is a middle-class emergency.

The Middle-Class Squeeze

The ADA’s data, gathered from a nationally representative sample, pulls back the curtain on who is bearing the brunt of these costs. The findings show that 44% of insulin-dependent individuals earning between $50,000 and $75,000 a year are paying over $150 each month for their insulin. That figure jumps to a staggering 55% for those earning between $75,000 and $99,000.

These are not abstract numbers. They represent families forced to reallocate funds from essential parts of their household budget. The survey’s broader findings reveal the devastating ripple effects: one in three respondents reported cutting back on groceries because of healthcare expenses. Nearly one in four has been forced to skip or delay a necessary medical appointment due to cost. The choice between a vial of insulin and a full pantry is one no American should have to make, yet it is a daily reality.

Patient advocates share stories of individuals watering down doses or skipping them entirely to make a vial last longer—a dangerous practice known as rationing that can lead to severe complications, including organ failure, blindness, and death. Recent studies estimate that as many as 1.3 million Americans have rationed their insulin due to cost, a statistic that underscores a profound public health failure.

A Patchwork of Protection and a Legislative Fix

Progress has been made, but it has been piecemeal. The Inflation Reduction Act of 2022 was a landmark achievement, capping insulin co-pays at $35 for those on Medicare. Additionally, 29 states and the District of Columbia have enacted their own cost-sharing limits for state-regulated plans. While commendable, these measures create a confusing patchwork of protection that leaves millions vulnerable—specifically, the more than 160 million Americans who receive health insurance through an employer.

Aiming to close this critical coverage gap is the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026. Reintroduced by a bipartisan group of senators including Jeanne Shaheen (D-NH), Susan Collins (R-ME), Raphael Warnock (D-GA), and John Kennedy (R-LA), the bill would extend the $35 monthly out-of-pocket cap to the commercial insurance market.

The legislation’s promise is significant, enjoying broad public support, with 76% of survey respondents across all political parties backing a $35 limit. The bill would also require health plans to waive deductibles for insulin products and includes provisions to support the uninsured, establishing pilot programs and a resource hotline. Crucially, it takes aim at the opaque system of pharmaceutical pricing by requiring Pharmacy Benefit Managers (PBMs) to pass 100% of the rebates they receive from drug manufacturers on to the health plans, a move designed to curb incentives for high list prices.

An Industry Under Scrutiny

The exorbitant price of insulin in the United States—five to ten times higher than in other developed nations—is the result of a complex and dysfunctional market dominated by three manufacturers: Eli Lilly, Novo Nordisk, and Sanofi. For years, these companies engaged in a pattern of lockstep price increases that defied market logic for a drug whose core formula has been available for decades.

Under immense public and political pressure, the industry has begun to shift. In 2023, Eli Lilly announced it was slashing the list price of its most popular insulins by 70% and capping out-of-pocket costs at $35. Sanofi and Novo Nordisk followed with similar commitments and expanded affordability programs. While these moves provide welcome relief, they are a tacit admission that the previously inflated prices were not tethered to the cost of production or innovation. They were, critics argue, simply what the market could be forced to bear.

Experts point to the perverse incentives created by PBMs, the powerful middlemen who negotiate drug prices. Their business model has historically favored drugs with high list prices because it allows them to extract larger rebates, a portion of which they keep as profit. The INSULIN Act’s focus on rebate pass-throughs is a direct attempt to dismantle this part of the system that fuels price inflation.

A Matter of Life and Death

The fight for affordable insulin is more than a debate over healthcare policy; it is a fight for human dignity and the right to survive. Advocacy groups have been relentless, turning personal tragedy into a powerful movement for systemic change. The ADA’s latest survey provides the data to back up what patients have been screaming for years: the system is broken.

“We've made extraordinary progress to reduce the cost of insulin in this country, but we're not done,” said Lisa Murdock, the ADA’s chief advocacy officer, in a statement accompanying the survey. “Half of insulin-dependent people with diabetes are still rationing, and three-quarters are paying more than $35 per month. No one should miss taking even one dose of a lifesaving medication because it is financially out of reach.”

As Congress considers the INSULIN Act, the numbers and stories from the front lines of this crisis serve as a powerful mandate for action. For millions of Americans, the passage of this bill is not a matter of politics, but a matter of survival.